Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using synthetic biology. The company operates primarily in the biotechnology and cell therapy industries, applying engineered gene circuits to enhance the precision, safety, and effectiveness of therapeutic cells. Its approach is designed to enable programmable biological responses, particularly in oncology.
The company’s core revenue drivers are currently research and development activities rather than commercial product sales, as its programs remain in clinical or preclinical stages. Senti Biosciences primarily targets patients with cancer, with an emphasis on solid tumors and hematologic malignancies. Founded in 2016 by synthetic biology researchers, the company emerged from academic research aimed at overcoming limitations of first-generation cell therapies and became a publicly traded company in 2022 following its initial public offering.
Business Operations
Senti Biosciences conducts its operations through a single integrated business focused on the discovery, development, and advancement of engineered cell therapies. Its primary operating segments include Gene Circuit Platform Development and Cell Therapy Product Development, with activities spanning early research through clinical trials. The company does not currently generate product revenue and relies on equity financing and strategic collaborations to fund operations.
The company’s proprietary technologies include its gene circuit platform, which enables logical control of cell behavior using Boolean logic gates, and engineered natural killer (NK) and T cell therapies. Its lead clinical candidate, SENTI-202, is an off-the-shelf CAR-NK cell therapy designed to selectively target acute myeloid leukemia cells while sparing healthy tissue. Senti Biosciences conducts operations primarily in the United States and maintains relationships with contract manufacturing and research organizations rather than large-scale in-house manufacturing.
Strategic Position & Investments
Senti Biosciences’ strategic direction centers on advancing its synthetic biology platform into clinical validation while expanding its pipeline of programmable cell therapies. Growth initiatives focus on progressing lead candidates through clinical trials, refining gene circuit capabilities, and developing additional oncology-focused programs that leverage its logic-gated control systems.
The company has made targeted investments in platform development rather than large acquisitions, emphasizing internal innovation. Notable pipeline programs beyond SENTI-202 include preclinical NK and T cell therapies aimed at solid tumors. Senti Biosciences positions itself as a differentiated player in the cell therapy space by addressing safety and specificity challenges that have limited broader adoption of engineered immune cells.
Geographic Footprint
Senti Biosciences is headquartered in South San Francisco, California, a major biotechnology hub in the United States. Its primary research, development, and corporate operations are based in this region, leveraging proximity to academic institutions, clinical partners, and biotechnology talent.
While the company’s physical footprint is largely domestic, its clinical development strategy has international relevance through potential global clinical trial sites and future commercialization pathways. As of the most recent public disclosures, the company does not report significant standalone international offices or manufacturing facilities outside the United States.
Leadership & Governance
Senti Biosciences was founded by leaders in synthetic biology with academic and industry experience, and its governance structure reflects a focus on scientific innovation and clinical execution. The leadership team emphasizes disciplined development, patient safety, and platform scalability as core elements of its strategic vision.
Key executives include:
- Timothy K. Lu – Co-Founder and Chief Executive Officer
- Wilson Wong – Co-Founder and Chief Scientific Officer
- Data inconclusive based on available public sources – Additional executive roles such as Chief Financial Officer and Chief Operating Officer are reported inconsistently across public disclosures and cannot be independently verified with certainty without updated filings.